• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Allergy Clin Immunol Pract . COVID-19 susceptibility in bronchial asthma

tetano

Editor, Senior Moderator
J Allergy Clin Immunol Pract


. 2020 Nov 23;S2213-2198(20)31240-X.
doi: 10.1016/j.jaip.2020.11.020. Online ahead of print.
COVID-19 susceptibility in bronchial asthma


Ilan Green[SUP] 1 [/SUP], Eugene Merzon[SUP] 1 [/SUP], Shlomo Vinker[SUP] 1 [/SUP], Avivit Golan-Cohen[SUP] 1 [/SUP], Eli Magen[SUP] 2 [/SUP]



Affiliations
Free PMC article

Abstract

Background: Bronchial asthma has not been adequately assessed in the coronavirus disease 2019 (COVID-19). Respiratory allergy is associated with significant reductions in ACE2 receptors expression, which is the entry receptor for COVID-19.
Objective: To observe COVID-19 susceptibility in patients with bronchial asthma, we have analyzed the prevalence of asthma in a large cohort of consecutive outpatient subjects who tested in the RT-PCR assay for COVID-19.
Methods: This was a retrospective population-based cross-sectional study utilizing data from a large nation-wide health maintenance organization (HMO) in Israel. All HMO enrollees who had been tested for COVID-19 from February to June 2020 were included. Differences in demographic and clinical characteristics between the subjects with negative and positive COVID-19 RT-PCR tests and between COVID-19 RT-PCR positive subjects with and without asthma were analyzed.
Results: A total of 37,469 subjects were tested for COVID-19 RT-PCR and 2,266 (6.05 %) of them were positive. A significantly higher proportion of smokers was observed in the COVID-19 negative group, than in the COVID-19 positive group (4,734 (13.45 %) vs 103 (4.55 %); p<0.001). Asthma was found in 153 (6.75 %) subjects of COVID-19 positive and in 3,388 (9.62 %) subjects of COVID-19 negative group (p<0.001). No significant impact of antileukotrienes, inhaled corticosteroids and long-acting beta-blockers use was revealed on COVID-19 positivity proportions. Multiple logistic regression analysis adjusted for sex, age, smoking, and comorbidity revealed a negative association of asthma with the likelihood of being positive for COVID-19 (OR 0.71 (95% confidence interval, 0.58-0.87); p=0.001).
Conclusion: we observed lower COVID-19 susceptibility in patients with pre-existing asthma.

Keywords: COVID-19; asthma; smoking; susceptibility.
 
Back
Top Bottom